Correction

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

N Engl J Med 2006; 354:778February 16, 2006

Article

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (Original Article, N Engl J Med 2004:350;1495 - 1504) . In Figure 2 on page 1500, several of the numbers of patients at risk for death or a major cardiovascular event in the pravastatin and atorvastatin groups were listed incorrectly. The numbers should have read as follows: for pravastatin, 1701 (6 months), 1542 (12 months), 1449 (18 months), 896 (24 months), and 224 (30 months); for atorvastatin, 1752 (6 months), 1590 (12 months), 1515 (18 months), 950 (24 months), and 231 (30 months).

Citing Articles (2)

Citing Articles

1. 1

   Marcelo J.A. Amar, Robert D. Shamburek, Boris Vaisman, Catherine L. Knapper, Bernhard Foger, Robert F. Hoyt, Silvia Santamarina-Fojo, Hollis B. Brewer, Alan T. Remaley. (2009) Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metabolism 58:4, 568-575
   CrossRef

2. 2

   C. RONCAL, J. ORBE, M. BELZUNCE, J. A. RODRíGUEZ, J. A. PÁRAMO. (2006) The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin. Journal of Thrombosis and Haemostasis 4:8, 1798-1803
   CrossRef